

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 July 2022 (28.07.2022)



(10) International Publication Number
WO 2022/157629 A1

(51) International Patent Classification:

A61K 31/519 (2006.01) A61K 31/4745 (2006.01)
A61K 45/06 (2006.01) A61K 31/506 (2006.01)
A61P 35/00 (2006.01) A61K 31/53 (2006.01)
A61K 31/517 (2006.01) A61K 31/5377 (2006.01)
A61K 31/337 (2006.01) A61K 31/555 (2006.01)
A61K 31/4439 (2006.01) A61K 31/704 (2006.01)
A61K 31/4545 (2006.01) A61K 31/7068 (2006.01)
A61K 31/47 (2006.01)

(21) International Application Number:

PCT/IB2022/050415

(22) International Filing Date:

19 January 2022 (19.01.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

202121002487 19 January 2021 (19.01.2021) IN

(71) Applicant: **LUPIN LIMITED** [IN/IN]; Kalpataru Inspire,
3rd Floor, Off Western Express Highway, Santacruz (East),
Maharashtra, Mumbai 400 055 (IN).

(72) Inventors: **BHONDE, Mandar Ramesh**; Lupin Research
Park, Survey No. 46A / 47A, Village Nande, Taluka Mulshi,
Maharashtra, Pune 412115 (IN). **PATRA, Sukanya**; A101,
Crown Signature, Nacharam, Uppal, Hyderabad 500076
(IN). **PALLE, Venkata P.**; Lupin Research Park, Sur-
vey No. 46A / 47A, Village Nande, Taluka Mulshi, Ma-
harashtra, Pune 412115 (IN). **KAMBOJ, Rajender Ku-**
mar; Lupin Research Park, Survey No. 46A / 47A, Village
Nande, Taluka Mulshi, Maharashtra, Pune 412115 (IN).

(74) Agent: **MAJUMDAR, Subhatosh** et al.; S. Majumdar
& Co., 5 Harish Mukherjee Road, State of West Bengal,
Kolkata 700 025 (IN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,

KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: PHARMACEUTICAL COMBINATIONS OF SOS1 INHIBITORS FOR TREATING AND/OR PREVENTING CANCER

(57) Abstract: This disclosure relates to pharmaceutical combinations for treating and/or preventing cancer and methods and uses thereof. More particularly, provided is a pharmaceutical combination comprising a SOS1 Inhibitor and an additional active ingredient selected from a KRAS inhibitor such as a KRAS G12C inhibitor and a KRAS G12D inhibitor, KRAS G13C inhibitor, and pan KRAS inhibitor; an EGFR inhibitor; an ERK1/2 inhibitor; a BRAF inhibitor; a pan-RAF inhibitor; a MEK inhibitor; a AKT inhibitor; a SHP2 inhibitor; protein arginine methyltransferases (PRMTs) inhibitor such as a PRMT5 inhibitor and Type I PRMT inhibitor; a PI3K inhibitor; a cyclin -dependent kinase (CDK) inhibitor such as CDK4/6 inhibitor; a FGFR inhibitor; a c-Met inhibitor; a RTK inhibitor; a non-receptor tyrosine kinase inhibitor; a histone methyltransferases (HMTs) inhibitor; a DNA methyltransferases (DNMTs) inhibitor; a Focal Adhesion Kinase (FAK) inhibitor; a Bcr-Abl tyrosine kinase inhibitor; a mTOR inhibitor; a PD1 inhibitor; a PD-L1 inhibitor; CTLA4 inhibitor; and chemotherapeutic agents such as gemcitabine, doxorubicin, cisplatin, carboplatin, paclitaxel, docetaxel, topotecan, irinotecan and temozolomide.

WO 2022/157629 A1